Forest Laboratories, Inc. FRX today announced positive topline
results from three Phase III trials evaluating the efficacy, safety and
tolerability of vilazodone in adult patients with generalized anxiety
disorder (GAD). In two flexible-dose and one fixed-dose GAD trials, patients
who received vilazodone demonstrated statistically significant improvement
from baseline in the Hamilton Rating Scale for Anxiety (HAM-A) total score
versus placebo at week 8, the primary endpoint.
"Forest is committed to helping people living with generalized anxiety
disorder and other mental health conditions. We have a growing mental health
portfolio and are one step closer to one day offering general anxiety
patients a new treatment option to help manage this condition," said Marco
Taglietti, M.D., Chief Medical Officer and EVP, Drug Development and
Research at Forest Laboratories, Inc.
Based on these results, the Viibryd supplemental New Drug Application (sNDA)
for the treatment of GAD will be filed with the FDA in 2015.
About the flexible-dose Phase III Study (MD-07)
This multicenter, randomized, double-blind, placebo-controlled,
parallel-group, flexible-dose, 8-week Phase III study evaluated the
efficacy, safety, and tolerability of vilazodone as treatment in adult
patients with GAD. Eligible patients were those who met Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision
(DSM-IV-TR) criteria for GAD, and had a minimum total score of 20 on the
HAM-A scale. Following a 7 day screening period, a total of 415 patients
between 18 and 70 years of age were randomized to one of two treatment
groups (vilazodone 20 - 40 mg/day, or placebo) followed by a 1-week
down-taper safety period. The primary endpoint was defined as change from
baseline to end of week 8 in the HAM-A total score. Statistically
significant improvement in the HAM-A total score was observed in the
vilazodone 20 - 40 mg/day group relative to the placebo group (Least squares
mean difference (LSMD): vilazodone 20 - 40 mg/day: -2.2, p=0.0048) using a
mixed-effect model for repeated measures (MMRM). Most common adverse events
in the vilazodone 20-40 mg/day group (incidence >=10 % and greater than
placebo) were nausea, diarrhea, headache, and dizziness.
About the flexible-dose Phase III Study (MD-06)
This multicenter, randomized, double-blind, placebo-controlled,
parallel-group, flexible-dose, 8-week Phase III study evaluated the
efficacy, safety, and tolerability of vilazodone as treatment in adult
patients with GAD. Eligible patients were those who met Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision
(DSM-IV-TR) criteria for GAD, and had a minimum total score of 20 on the
HAM-A scale. Following a 7 day screening period, a total of 402 patients
between 18 and 70 years of age were randomized to one of two treatment
groups (vilazodone 20 - 40 mg/day, or placebo) followed by a 1-week
down-taper safety period. The primary endpoint was the change from baseline
to end of week 8 in the HAM-A total score. Statistically significant
improvement in the HAM-A total score was observed in the vilazodone 20 - 40
mg/day group relative to the placebo group (Least squares mean difference
(LSMD): vilazodone 20 - 40 mg/day: -1.50, p=0.0438;) using a mixed-effect
model for repeated measures (MMRM). Most common adverse events in the
vilazodone 20-40 mg/day group (incidence >=10 % and greater than placebo)
were nausea, and diarrhea.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in